In addition, two out of the four ATP13A3 variant carriers also carried a nonsense mutation in the BMPR2 gene (A100593 and A100719), which demonstrated the speculative contribution of the two ATP13A3 variants to PAH instead of the observed effect despite the small sample size. Here, ATP13A3 is linked to pulmonary arterial hypertension.